


**Please cite the Published Version**

Ashbrook, Jane, Rogdakis, Nikos, Callaghan, Michael J, Yeowell, Gillian  and Goodwin, Peter Charles (2020) The therapeutic management of back pain with and without sciatica in the emergency department: a systematic review. *Physiotherapy*, 109. pp. 13-32. ISSN 0031-9406

**DOI:** <https://doi.org/10.1016/j.physio.2020.07.005>

**Publisher:** Elsevier BV

**Version:** Accepted Version

**Downloaded from:** <https://e-space.mmu.ac.uk/626225/>

**Usage rights:**  In Copyright

**Additional Information:** This is an Author Accepted Manuscript published in *Physiotherapy*.

**Enquiries:**

If you have questions about this document, contact [openresearch@mmu.ac.uk](mailto:openresearch@mmu.ac.uk). Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

# The Therapeutic Management of Back Pain With and Without Sciatica in the Emergency department: A Systematic review

## Running title

Back pain in the Emergency Department

## Introduction

There were 23.8 million attendances in Emergency Departments (ED) in England in 2017-18 (1). The number of patients re-attending within 7 days in 2018-18 was 1.7 million; this is an overall increase since 2008-09 of 86 percent. This is impacting on the National Health Service (NHS) constitution target of 95 percent of patients spending 4 hours or less in the ED, which has not been met since 2013-14 (1).

There are no specific data pertaining to numbers of patients with low back pain, with or without sciatica, attending the ED in the United Kingdom (UK) due to recording of diagnostic categories in national statistics not specifying the anatomical region of musculoskeletal problems. Epidemiological data from the United States of America (USA) have reported an estimated 2.06 million episodes of low back pain per year, accounting for 3% of all emergency department visits (2). In Australia, back pain is reported to be in the top 10 conditions presenting in the ED (3). In most ED back pain cases, despite increasing use of diagnostic tests, such as plain film radiographs, Magnetic Resonance Imaging (MRI) scans and blood tests with direct costs estimated at US\$819 million (4), the specific cause of patient symptoms is never established (5, 6). The lack of diagnosis and management guidelines results in significant physical and emotional burden to the patient and challenge to the treating physician (3). It is recommended specific imaging modalities be reserved exclusively to exclude serious conditions (5).

In the absence of specific guidance, there is evidence to suggest the existence of varied and inconsistent management of back pain with or without sciatica in the ED (6). Although guidelines

suggest opioids be reserved for severe pain (7), evidence suggests their use in the ED has increased and the use of non-steroidal anti-inflammatories has decreased (4, 5).

Physiotherapy management of musculoskeletal conditions, has been recommended as a potentially clinically and cost effective addition to the ED Multi-Disciplinary Team (MDT) (8). Physiotherapists as primary contact practitioners in the ED have demonstrated effective management of back pain with or without sciatica, with significantly less ED length of stay (EDLOS) and fewer imaging requests than medical staff (9).

The importance of establishing some recommendations for the management of low back pain with or without sciatica in the absence of clinical red flags or serious pathology in the ED would be helpful to patients and clinicians. A MDT approach to health care is becoming increasingly commonplace and there is a growing body of evidence suggesting that inter-professional teamwork in the ED could be beneficial in reducing LOS and unnecessary imaging (8-10).

## **Objectives**

The purpose of this study was to review the available literature to determine the evidence base for therapeutic management of adults presenting with back pain with or without sciatica in the ED. The outcomes of interest included pain, function, EDLOS, adverse events and continued resource utilisation such as re-attendance in the ED.

## **Method**

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were taken into account to enhance the quality of this review. The review protocol was made publicly available on the PROSPERO website.

## **Search Strategy**

The following databases were searched: MEDLINE [via IVIDSP 1946-], EMBASE [via EBSCOhost 1974-], SCOPUS [1996-], CINAHL [via EBSCOhost 1981-], ZETOC [1993-], PubMed, The Cochrane Library

(Cochrane Database of Systematic Reviews), Web of Science, Open Grey and ETHOS. Searches were from inception to August 2018. Search terms were (Low Back Pain) OR (Lumbago) OR (Sciatica) OR (Radiculopathy) AND (Emergency Department) OR (Accident and Emergency) OR (A&E) AND (Treatment) OR (Management) including MeSH.

### **Inclusion and exclusion criteria**

Included were, peer reviewed, original research in the English Language. All studies including adult patients (> 16 years) with low back pain in the ED with validated outcome measures were included. Radicular leg pain could be present or absent. All therapeutic interventions were evaluated. Pilot studies were included.

Studies were excluded if they addressed the management of patients with red flags suggestive of serious spinal pathologies such as **cauda equina syndrome**, cancer or infection, rheumatoid or inflammatory arthropathies, pregnancy, low back pain resulting from major trauma and abdominal aortic aneurysm. Studies set in primary care, GP surgeries, hospital wards and emergency transport were excluded. Studies evaluating diagnostic and imaging interventions were excluded. Other exclusions included systematic and narrative reviews, clinical commentaries, editorials, grey literature or studies from non-peer reviewed journals. Reference lists of the full text articles were checked to ensure any articles not captured in the electronic search were included. No publication date limits were set.

### **Study selection and quality assessment scheme**

Two reviewers (JA/NR) searched the databases independently. Articles were reviewed for eligibility based on their title, abstract and then full text. Non-eligible studies were excluded and duplicate articles were removed (Fig. 1).

### **Data extraction**

Two reviewers (JA/NR) extracted key data from the articles independently and third and fourth reviewers (PG/GY) acted as arbiters. Key data were summarised to allow comparison and contextualisation of results (Tables 1 and 2).

### **Assessment of Study Quality**

The final studies were appraised for methodological quality by the two reviewers (JA/NR) independently using the Downs and Black checklist (11), **any disagreement in scores resolved by discussion. Third and fourth reviewers (GY/PG) were available to resolve disagreements; however, this was not required.** The Downs and Black checklist has a Spearman Correlation Coefficient 0.90 for assessing the methodological quality of randomized and non-randomized studies (12). The checklist has five sections: reporting, external validity, internal validity, selection bias and power. Each section has a maximum score of 11, 3, 7, 6 and 5 points, respectively, or total score of 32 points.

### **Results**

An initial search identified **2384** articles on a variety of topics on the ED management of acute low back pain with or without sciatica. After removing duplicates and excluding those not matching the inclusion criteria, a total of **26** articles were identified including **5429** patients, spanning eight countries (Table 1 and 2). The outcome measures, interventions and comparators used in these trials were heterogeneous, therefore, a narrative review was deemed be the most appropriate method to report the findings.

Out of the final **26** studies there were **19** randomised control trials, **2 randomised studies (no control)**, one randomised control pilot study, two cohort studies, one cohort pilot study and one retrospective audit.

**Figure 1: Flowchart depicting the database search and article elimination process, along the guidelines of PRISMA.**

**Table 1: Pharmacological interventions PICOS**

## Table 2: Non-pharmacological interventions PICOS

### 1 **Methodological quality of the trials**

2 Methodological quality is summarised in Tables 3 and 4. Study scores ranged from 16 to 31 with a  
3 mean score of 24 out of a possible 32 and given corresponding quality levels: excellent (27-32), good  
4 (21-26), fair (15-20) and poor (<15) adapted from previously documented ratings (13).

### 5 **Randomisation and Concealment**

6 Computer generated randomisation was used in 20 studies, one study (14) used manually shuffled  
7 sealed, opaque envelopes and two studies (15, 16) did not state how randomisation occurred.

8 Sealed opaque envelopes were used to conceal randomisation in nine studies (14, 16-22). Identical or  
9 labelled syringes or masked tablets were provided immediately after randomisation by the pharmacist  
10 in seven studies (23-27).

### 11 **Intention-to-Treat Analysis**

12 Two studies excluded from their analysis participants with missing data who either withdrew from the  
13 study or failed to record outcome (18, 28) and one (15) did not clarify data analysis approach following  
14 drop outs.

### 15 **Blinding**

16 Of the seventeen pharmacological RCTs double blinding occurred in fifteen. In two studies (18, 23) only  
17 the patient was blinded to treatment. In two studies (29, 30) multiple superficial injections were  
18 compared to a single infusion and no blinding occurred.

19 Of the acupuncture studies one (31) attempted to blind the participants by providing sham  
20 acupuncture, one (32) blinded the outcome assessors and acupuncturists to pharmacological therapy  
21 and one (14) made no attempt at blinding. The outcome assessors only were blinded in the  
22 physiotherapy intervention study (33). This lack of blinding increases the risk of bias in these studies.

23

24

25 **Table 3: Downs and Black scores of pharmacological studies.**

26 **Table 4: Downs and Black scores of non-pharmacological studies.**

27 **Pharmacological studies**

28 **Twenty-one** studies, including **3482** patients, investigated the pharmacological management of back  
29 pain in the ED. Mean methodological score was 26 (Table 3). **There were n=11 studies of excellent**  
30 **quality. N=2** (17, 20) **found** corticosteroids to be beneficial in LBP with sciatica, but not LBP without  
31 sciatica. **When considering the use of oral and topical non-steroidal anti-inflammatory drugs**  
32 **(NSAIDs) in the management of LBP without sciatica n=3 studies** (23, 24, 26) **found** Naproxen to be  
33 superior alone when compared to combination pharmacotherapy, **the addition of paracetamol to**  
34 **ibuprofen compared to ibuprofen alone did not improve outcomes after one week(34), and n=1**  
35 **study found the application of Ketoprofen gel in addition to intravenous (IV) Dexketoprofen to be**  
36 **superior to placebo (27). IV Dexketoprofen NSAID) was as effective as IV Paracetamol and IV**  
37 **Morphine in patients with LBP without neurological deficit(19) in n=1 study. N=4** (23, 24, 26, 35)  
38 studies concluded that muscle relaxants are not helpful in the management of LBP without sciatica  
39 and there were no studies investigating the use of muscle relaxants in LBP with sciatica. **IV Morphine**  
40 **was found to be superior to IV paracetamol in patients with LBP with sciatica and the same adverse**  
41 **effect profile in n=1 study (21). N=1 study found that at least fifty trigger point injections of a**  
42 **combination of Thiocolchicoside, Lidocaine and Tenoxicam was more effective in reducing pain up to**  
43 **one hour compared so a single dose of IV Dexketoprofen (29) (Table 5).**

44 Studies included male and female adults aged 18 and over. Thirteen studies included only patients  
45 with acute and severe pain identified by duration of pain and minimum score on a pain **Visual**  
46 **Analogue Scale** (VAS) or **numerical pain rating scale** (NPRS), however minimum scores were

47 inconsistent throughout the studies. **Six** studies excluded patients without sciatica (17, 20, 21, 28,  
48 29, 36), **twelve** studies excluded patients with sciatica (18, 19, 23-27, 30, 34, 35, 37) and the  
49 remaining studies did not specify the presence or absence of sciatica in their inclusion or exclusion  
50 criteria.

51 All studies recorded short-term outcomes measures ranging from 15 minutes to 7 days including  
52 pain severity, function, adverse events, use of rescue analgesia, EDLOS, patient satisfaction and  
53 healthcare utilization. Long-term outcomes were measured in **16** studies ranging from one week to  
54 three months.

55

#### 56 **Table 5: Grouped positive and negative finding of pharmacological studies**

##### 57 **Non-Pharmacological studies**

58 Five studies, (2034 patients) investigated the non-pharmacological management of back pain in the  
59 ED. Mean methodological score was 21.6 (Table 4). Two fair quality studies (24, 35) concluded that  
60 Physiotherapy assessment and treatment was superior to standard care on discharge and at 1  
61 month. One excellent quality study (32) concluded that acupuncture does not enhance pain relief  
62 when alone or combined with pharmacological management and two acupuncture studies (16, 31)  
63 of fair quality concluded that acupuncture is effective for short-term pain relief (Table 6).

64 Studies included male and female adults aged 18 and over. Only one study specified a minimum pain  
65 score for inclusion criteria. Two physiotherapy studies (24, 35) included patients with back pain with  
66 or without radicular pain. Three acupuncture studies included patients with back pain only.

67 All studies recorded short-term outcomes and four studies recorded follow up outcomes ranging  
68 from 48 hours (32) to 6 months (24). The outcome measures focused on pain, function and adverse  
69 events. Two studies (32, 35) considered EDLOS and ongoing resource use, such as admission rate  
70 and rescue analgesia.



71 **Table 6: Grouped positive and negative finding of non-pharmacological studies**

72 **Discussion**

73 The purpose of this systematic review was to determine the evidence base for the therapeutic  
74 management of adults attending the ED with back pain with or without sciatica.

75 Low back pain with or without sciatica is recognized as a major financial burden because of the  
76 resources needed for its management, including imaging, increased ED length of stay, ongoing  
77 analgesic management, healthcare utilisation and potential hospital ward admission(4).

78 Despite the studies reviewed spanning eight countries there are no data to determine the  
79 prevalence or management of LBP in the ED in the UK.

80 **Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)**

81 Findings from this review that NSAIDs are as effective alone than when combined with other  
82 pharmacology (23, 26, 27, 38, 39) are consistent with the recommendations of others (40, 41). It is  
83 recommended that oral NSAIDs should be considered first in the ED management of patients with  
84 back pain and that the addition of opioids or muscle relaxants do not significantly affect pain-  
85 relieving qualities (40). The National Institute of Clinical Excellence (NICE) (41) goes further and  
86 states that patients with LBP should be managed in primary care without the need to burden an  
87 already overstretched ED.

88 None of the studies comparing Naproxen to muscle relaxants sub-classified patients into those with  
89 spasm and those without. Therefore, the effect of adding muscle relaxants in the presence of muscle  
90 spasm was not established.

91 Two studies of varied quality indicate that IV NSAIDs are as effective as other parenteral drugs  
92 without a significant adverse effect profile (19, 28); however, no studies compare the efficacy of IV  
93 to oral in terms of pain relief, EDLOS and ongoing resource use.

94 One high quality study (27) concluded that adding Ketoprofen gel to IV dexketoprofen significantly  
95 improved pain relief at 30mins; however, functional outcomes, long-term outcomes or EDLOS were  
96 not reported.

## 97 **Opioids**

98 While there is no doubt that IV morphine is effective in the management of back pain in the ED,  
99 there is conflicting evidence regarding its superiority (19, 21). Both studies reported similar adverse  
100 events including nausea, vomiting and dizziness. Due to rare but unpredictable serious adverse  
101 events (42), patients require lengthy monitoring post IV administration of morphine resulting in  
102 potentially higher EDLOS than that of other analgesia. Unfortunately, neither studies included EDLOS  
103 as an outcome measure making it impossible to determine this.

104 Acetaminophen-codeine is found to be of no greater benefit to pain relief when combined with  
105 NSAIDs and has a greater adverse effect profile (23, 39) making it a poor choice of management.

106 Tapentadol and Tramadol were both effective resulting in significant pain reduction after 7 days and  
107 3 months in one moderate quality study (43). Patients who received Tapentadol demonstrated  
108 reduced re-attendance rates **30 days** following discharge.

109 Although there seems to be a place for opioids in this population these results are in line with clinical  
110 guidance advising use be reserved for severe and disabling pain that is not controlled with first line  
111 management (7). Essential considerations for prescribing opioids on discharge must include  
112 increasing rates of opioid prescription in primary care and the association with abuse, serious  
113 adverse effects and premature death (38), particularly in this patient group where a significant  
114 proportion will continue to access healthcare in the long term.

## 115 **Corticosteroids**

116 For patients presenting with back pain in the absence of neurological deficit oral prednisolone was  
117 not effective in the reduction of pain and resulted in more medical management and greater

118 number of days off work (34). For patients presenting with back pain without radicular symptoms  
119 there were no benefits to intra-muscular (IM) methylprednisolone when administered in addition to  
120 standard care (28).

121 For patients presenting with radicular back pain in the ED some benefits pertaining to the use of  
122 corticosteroids have been documented. IV dexamethasone significantly reduced 24-hour pain and  
123 EDLOS (19) in one high quality study, while IM methylprednisolone significantly reduced disability  
124 and analgesic use in a study with poor selection bias and no reported power calculation. This  
125 observation needs to be investigated further, perhaps leading to the stratification of low back  
126 patients based on radicular symptoms.

### 127 **Physiotherapy**

128 Physiotherapists have become increasingly common in the ED team, particularly in the UK, USA and  
129 Australia (12).

130 The utilization of physiotherapists with advanced competencies as first contact practitioners in the  
131 ED has shown positive results in one moderate quality study (35). Patients assessed by advanced  
132 musculoskeletal physiotherapists had less EDLOS and were less likely to be admitted to a hospital  
133 ward compared to patients seen by doctors or nurse practitioners, without evidence of re-  
134 attendance.

135 Implementing physiotherapy management in the ED for patients with and without sciatica resulted  
136 in significantly improved pain and function on discharge and 1 month follow up compared to usual  
137 care (24). The intervention group received advice, pain education and reassurance as well as  
138 practical guidance on returning to usual activities and coping strategies in line with NICE guidance  
139 (41). Although this study supports early physiotherapy intervention in the ED due to difficulty  
140 blinding participants and physiotherapists and a lack of power calculation, a moderate risk of bias  
141 must be considered when interpreting these results.

142 **Acupuncture**

143 In one high quality study, acupuncture was found to be of no benefit in addition to  
144 pharmacotherapy (32). The group receiving acupuncture in isolation required significantly more  
145 rescue analgesia and were more likely to be admitted onto a hospital ward. These findings suggest  
146 that acupuncture is not likely to enhance the management of back pain in the ED.

147 **Strengths and limitations of the study**

148 This was a rigorous systematic review following PRISMA guidance with prior publication in  
149 PROSPERO. Two reviewers independently searched the databases, extracted the data and reviewed  
150 the literature for quality with third and fourth arbiters. An evidence-based risk of bias tool was used  
151 to evaluate the heterogeneous studies and a narrative approach to reporting the findings was taken  
152 according to recommendations.

153 Despite this, limitations existed. The reviewers were not blinded to publication information (e.g.  
154 authors and institution names). Despite our best attempt at being systematic and complete in our  
155 searches, we excluded five articles that were not in English. These two issues potentially introduce  
156 cultural, language and/or publication bias.

157 **Conclusion**

158 **This review has identified that there is a lack of understanding of the prevalence of back pain**  
159 **attendances in the UK ED. Prior to undertaking trials investigating the management of LBP in the ED**  
160 **in the UK basic epidemiological data on numbers attending is required.**

161 The available literature regarding the therapeutic management of acute low back pain with or  
162 without sciatica in the ED **has been summarised** in this review. The evidence suggests for patients  
163 presenting with back pain and no radicular symptoms Naproxen should be considered as first line  
164 pain relief. IV morphine, paracetamol or dexketoprofen could be considered in this group in rare  
165 cases of severe pain where first line treatment is unsuccessful.

166 For patients presenting with radicular symptoms, first line analgesic management is not clear from  
167 the literature. In cases of severe pain IV corticosteroids could be considered.

168 The literature indicates physiotherapy assessment and interventions may be effective in improving  
169 EDLOS, pain and functional outcomes in LBP patients with and without radicular symptoms.  
170 However, in order to establish whether physiotherapy can be recommended as part of an evidence-  
171 based management protocol for the treatment of acute LBP with or without sciatica in the ED, high  
172 quality trials are required.

173 Further studies to investigate the pharmacological management of LBP without radicular symptoms  
174 are not recommended.

175 **Ethic approval and consent to participate**

176 Not applicable.

177 **Conflict of interests**

178 The authors declare that they have no conflicts of interest.

179

180 **Funding sources**

181 This project was unfunded

182

183 **Acknowledgements**

184 Not applicable.

185

186

187

188

189

190

191

192

193

194


195

196

197

198 **Figure 1: Flowchart depicting the database search and article elimination process, along the**

199 **guidelines of PRISMA.**



214

215

216 **Table 1: Pharmacological interventions PICOS**

Authors, publication year, country, study design	Participants	Interventions	Comparisons	Outcomes
Akbas, et al (2019, Turkey) Non-blinded randomised study (29)	N=120 Median age: 36 Female: n=56 Acute LBP with confirmed disc herniation and positive straight leg raise	<u>Group 1:</u> >50 mesotherapy injections 1-3mm depth of 0.1 to 0.2cc. 2mg thiocolchicoside, 16.2mg lidocaine, 5mg tenoxicam Minimum 50 injections	<u>Group 2:</u> 50mg dextketoprofen in 100cc isotonic solution IV for 5 minutes.	<u>Mean delta values of pain VAS score reduction:</u> 15 minutes: G1 2.13 (SD 1.46), G2 1.32 (SD 0.85) p=0.001 30 minutes: G1 3.70 (SD 1.98), G2 2.18 (SD 1.08) p<0.001 60 minutes: G1 4.68 (SD 2.14), G2 2.97 (SD 1.15) p<0.001 24 hours: G1 6.08 (SD 1.87), G2 3.92 (SD 1.43)  Adverse events: G1 4, G2 8 all transient and resolved appropriately.
Balakrishna moorthy et al (2015, Australia) Double-blind Randomised Controlled Trial (RCT) (17)	N=58. Radicular low back pain. Female: n=28 Aged 18-55. Positive SLR test. Difficulty mobilizing.	<u>Group 1(G1):</u> 8mg IV dexamethasone.  Standard care: regular analgesia, education, physiotherapy referral.	<u>Group 2 (G2):</u> 2ml IV 0.9% sodium chloride.  Standard care: regular analgesia, education, physiotherapy referral.	<u>24 hours:</u> Pain VAS: 1.86 point greater reduction in group 1 (95% CI 0.3 to 3.4, p=0.02) EDLOS: Shorter in G1 (median 3.5 vs 18.8hrs, p=0.049) SLR ROM: G1: 14.7° greater improvement (95% CI 1.3 to 34.3, p=0.04) ODI: -3 mean diff (95% CI -15.1 to 9.1 p=0.62). * <u>6 weeks:</u> Pain VAS: Significant improvement in pain both groups. G1: -4.28 (95% CI -6.2 to -2.54, p<0.001). G2: -2.83 (95% CI -4.37 to -1.28, p<0.001). * ODI: 2.9 mean diff (95% CI -13.4 to 19.3, p=0.72) * Ability to return to normal activities: 74% vs 60%, p=0.3. * Adverse events: G1: 18%. G2: 15%. All mild.
Behrbalk et al (2014, Israel) (18)	N= 59 Acute LBP Female: n=35 Age: 18-65	<u>Group 1:</u> 0.1mg/kg, up to 10mg IV morphine with 25mg	<u>Group 2:</u> 0.1mg/kg, up to 10mg IV morphine in 150ml normal saline solution over 30 minutes	<u>2 hours:</u> Pain VAS: G1 vs G2: 4mm less reduction in pain (95%CI -3 to 11) p=0.26 Anxiety VAS: G1 vs G2: 6mm less reduction in anxiety (95%CI -7 to 19) p=0.37

Single-blind RCT	No neurological deficit Baseline VAS $\geq$ 70mm	promethazine, in 150ml normal saline solution over 30 minutes		EDLOS: G1 vs G2: 78mins increase (95%CI 16-140) p=0.01. Significant increase Gp1.  Patient satisfaction VAS: G1 vs G2: 4mm less (95%CI -5 to 13) p=0.39. * Adverse events: G1 vs G2: 73.1% increase (50-85) p<0.001. Significantly more drowsiness and sedation in G1.
Eken et al (2014, Turkey)  Double-blind RCT (19)	N=137 LBP (4-pt VRS: mod/sev). Acute (last week). Female: n=54. Age: 18-55. No neurological signs. No analgesia previous 6hr	<u>Group 1:</u> IV paracetamol 1g in 100ml saline solution.  <u>Group 2:</u> IV morphine 0.1mg/kg in 100ml saline solution.	<u>Group 3</u> IV dexketoprofen 50mg in 100mg saline solution	<u>15 mins:</u> Pain VAS: G1 vs G2: 11.3 mean diff (95% CI 1 to 22). Gp2 vs Gp3: 15.3 mean diff (95%CI -25 to 6). G1 vs G3: 4 mean diff (95%CI -13 to 5). * <u>30 mins:</u> Pain VAS: G1 vs G2: 3.8 mean diff (95%CI -6 to 14). G1 vs G3 7.4 mean diff (95%CI -18 to 3). G2 vs G3: 11.2 mean diff (95%CI 2 to 21). * Rescue analgesia: Group 1: 17.4%, group 2: 4.4%, group 3: 15.2%. P=0.135. * Adverse effects: Group 1: 8.7%, group 2: 15.5%, group 3: 8.7%. P=0.482. *
Ergün et al (2010, Turkey)  Double-blind RCT (15)	Short-term: n=72. Long-term: n=61. LBP Short term: female: n=45 Long-term: female: n=39 Age: 18-55 Normal blood markers No muscle relaxant or NSAID use in past 12 hrs	<u>Group 1:</u> Acute: Oral 2 x 400mg sugarcoated phenylramidol tablets. Chronic: Oral 400mg phenylramidol. TTD 3, 7 days  Rescue: Oral 20 x 275mg naproxen sodium TTD max 4.	<u>Group 2:</u>  Acute phase: Intramuscular 800mg phenylramidol ampoule.  Chronic phase: Placebo.  Rescue analgesia: Oral 2 x 275mg naproxen sodium TTD max 4	<u>Acute phase 2hrs:</u> Pain VAS: Pain reduction between groups p=0.624. *  Pharmacokinetic parameters: *  Adverse effects: 11% of patients in each group suffered mild/mod.  <u>Chronic phase 1 week:</u> Rescue analgesics: Less than 1 per day. * Median global evaluation score: "Mildly effective" patients and physicians both gps. Adverse effects: 7/38 patients in group 2 showed elevated liver enzymes, resolving with no treatment 7 days later.
Eskin et al (2014, USA)  Double-blind RTC	N=79 24hr history of LBP Female: n=24 Age: 18 to 55 Pain >5 VAS	<u>Group 1:</u> Oral 50mg prednisone, and 4 x 50mg oral prednisone to	<u>Group 2:</u> Oral placebo tablet, and 4 placebo tablets to take home, to use one per day.	<u>5-7 days:</u> 3-point pain VRS: G1 vs G2: 0.2 mean diff (95%CI -0.2 to 0.6) p=0.25. * Further medical care: G1 vs G2: 22% mean diff (95%CI 0 to 43%) p=0.05. Significantly more patients in the prednisolone group sought further medical care than in the placebo group.



(37)	No neurological motor deficits. No current use of steroids	take home, to use one per day.  Analgesic therapy in ED: physician's judgement, not corticosteroids.	Analgesic therapy in ED: physician's judgement, not corticosteroids	Days lost to work: G1 vs G2: 0.9 mean diff (95%CI -0.1 to 1.8) p=0.06. * Resumed normal activities: G1 vs G2: 0%mean diff (95%CI -23 to 23) p=1 * Returned to work: G1 vs G2: -1%mean diff (95%CI -22 to 19) p=0.95 * Patient satisfaction: G1 vs G2: 0.0%mean diff (95%CI -0.2 to 0.3) p=0.90 * Adverse effects: None reported in either group.
Friedman et al (2006, USA)  Double blind RCT (25)	N=87 Non radicular LBP <7 day History Female: 51 Age: 21 to 50 No corticosteroid use	<u>Group 1:</u> IM 160mg methylprednisolone acetate. Standard care: as above.	<u>Group 2:</u> IM 160mg placebo.  Standard care: as above	<u>1 week:</u> Past 24-hour pain NRS: 0.6 mean difference between groups (95%CI -0.9 to 2.2) * RMDQ-18=0: G1 71% vs G2 74% Return to usual activities: G1 87% vs G2 79%. * Adverse effects: 24% diff btwn Gps (95% CI, 16 to 35). Worse in G1. % pain free patients: G1 33 vs G2 40%. * <u>1 month:</u> Pain NRS: 0.6 mean diff(95%CI -1 to 2.2) * RMDQ-18=0: G1 77% vs G2 74%. * Return to usual activities: G1 85% vs G2 80%. * %pain free: G1 55% vs G2 57%. *
Friedman et al (2008, USA)  Double-blind RCT (20)	N=82 Non-recurrent radicular LBP <7 day history Female: n=43 Age: 21 to 50 Positive SLR (30-70°) No corticosteroid use	<u>Group 1:</u> IM 160mg methyl-prednisolone acetate.  Standard care: 14 x 500mg naproxen twice daily, 14 x oxycodone 5mg/acetaminophen as needed, LBP instruction sheet.	<u>Group 2:</u> IM 160mg placebo.  Standard care: 14 x 500mg naproxen twice daily, 14 x oxycodone 5mg/acetaminophen as needed, LBP instruction sheet	<u>1 week:</u> Past 24-hour pain NRS: G1 vs G2: 1.1 mean reduction (95%CI -0.5 to 2.8) p=0.16.* Disability self report: G1 vs G2: 19% reduction (95%CI -4 to 42) Adverse effects: Gp1 vs Gp2: 32% vs 24%, (95%CI for diff 9%, -12 to 30) <u>1 month:</u> Past 24-hour pain NRS: G1 vsG2: 1.3 mean reduction (95%CI -0.2 to 2.7) p=0.10. * Disability self report: G1 vs G2: 29% reduction (95%CI 9 to 49) p=0.007. Significant difference between groups.  Analgesic use 24 hours: G1 vs G2: 20% reduction (95%CI 0 to 40) p=0.06 Not yet resumed usual activities: G1 vs G2: 9% reduction (95%CI -9 to 27) p=0.34 *

<p>Friedman et al (2015, USA)</p> <p>Single-blind RCT (23)</p>	<p>N=323</p> <p>Acute musculoskeletal LBP</p> <p>Non-traumatic Non-radicular</p> <p>Female: n=158</p> <p>Age: 21 to 64</p> <p>RMDQ score &gt;5</p>	<p><u>Group1:</u></p> <p>Oral 60 x 5mg cyclobenzaprine tablets, 1 or 2 tablets every 8 hours, as needed.</p> <p><u>Group2:</u></p> <p>Oral 60 x 325mg oxycodone 5mg/acetaminophen tablets, 1 or 2 tablets every 8 hours, as needed.</p> <p>Both groups: Oral 20 x 500mg naproxen tablets, 1 every 12 hours</p>	<p><u>Group3:</u></p> <p>Oral 60 x placebo tablets, 1 or 2 tablets every 8 hours, as needed.</p> <p>Oral 20 x 500mg naproxen tablets, 1 every 12 hours.</p>	<p><u>7 days:</u></p> <p>RMDQ: G1 vs G3=0.3(98.3% CI -2.6-3.2) p=0.77. G2 vs G3=1.3 (98.3% -1.5 to 4.1) p=0.28. G1 vs G2=0.9 (98.3% CI -2.1 to 3.9) p=0.45. *</p> <p>No. day usual activity: G1=4, G2=4, G3=5.</p> <p>No. days return to work: G1=3, G2=2, G3=3.</p> <p>Worse LBP 24hrs mod/sev: G1=43%, G2=38%, G3= 49%.</p> <p>Frequency LBP (frequently/always): G1=31%, G2=30%, G3=37%.</p> <p>Use of medication: G1=62%, G2=59%, G3=68%.</p> <p>Adverse effects: G1 vs G3: 19% more adverse events (95%CI 7 to 31). G2 vs G3: 13% more adverse events (95%CI 1 to 25).</p> <p><u>3 months:</u></p> <p>RMDQ: G1 vs G3= 0.6 (-1.3 to 2.6), G2 vs G3= 0.8(-1.1 to 2.7), G1 vs G2=0.2(-1.9 to 2.2) mean % diff (CI 95%).</p> <p>Worse LBP 72hrs % (mod/sev): G1=27, G2=21, G3=28.</p> <p>Frequency LBP 72hrs %(freq/always): G1=12, G2=18, G3=19. Use of meds %: G1=26, G2=20, G3=28.</p> <p>Use of medication 72hrs: G1 vs G3: reduction of 2(95%CI-10 to 14) G2 vs G3: reduction of 8(95%CI -3 to 19)</p>
<p>Friedman, B. et al (2017, USA)</p> <p>Randomised , double blind, comparative efficacy trial. (24)</p>	<p>N=114</p> <p>Age: 21 to 69 (mean=36).</p> <p>Non-traumatic, non-radicular, musculoskeletal LBP. RMDQ&gt;5. Pain &lt;2 weeks.</p>	<p><u>Group 1:</u></p> <p>Naproxen 500mg tablets taken twice per day.</p> <p>Diazepam 5mg taken as 1 or 2 tablets every 12 hours for 7 days.</p>	<p><u>Group 2:</u></p> <p>Naproxen 500mg tablets taken twice per day.</p> <p>Placebo taken as 1 or 2 tablets every 12 hours for 7 days.</p>	<p><u>1 week:</u></p> <p>RMDQ: Mean improvement: G1 11(95%CI 9 to 13) vs G2 11 (95%CI 8 to 13). *</p> <p>Median days return to usual activity: Diff between groups: -0.4 (95%CI -0.6 to 1.4) *</p> <p>Worst LBP 24hrs: 4 item ordinal scale. Diff between groups: -10 (95%CI -26 to 7) *</p> <p>Frequency of LBP 24hrs: 3 item ordinal scale. Diff between groups: -6 (95%CI -25 to 12) *</p> <p>Use of medication: Diff between groups: 0 (95%CI -19 to 18) *</p> <p>Adverse events: Diff between groups: 6 (95%CI -9 to 20) * No serious or unexpected adverse events.</p> <p><u>3 months:</u></p> <p>RMDQ: Median score G1: 0, G2: 0. Diff between groups: -2 (95%CI -4.2 to 0.3)*</p> <p>Worse LBP 72hrs: Diff between groups: -3 (95%CI -15 to 9) *</p> <p>Frequency LBP 72hrs: Diff between groups: 5 (95%CI -10 to 20) *</p> <p>Use of medication 72hrs: Diff between groups: -5 (95%CI -18 to 9) *</p>

<p>Friedman, B. W. et al (2018, USA)</p> <p>Randomised, double blind, comparative effectiveness trial. (26)</p>	<p>N=240</p> <p>Age: 18 to 69 (mean 39)</p> <p>Non-traumatic, non-radicular, musculoskeletal LBP</p> <p>RMDQ &gt;5</p> <p>Pain duration &lt;2 weeks</p>	<p><u>Group 1:</u></p> <p>Naproxen 500mg twice per day.</p> <p>Orphenadrine 100mg twice per day.</p> <p><u>Group 2:</u></p> <p>Naproxen 500mg twice per day.</p> <p>Methocarbamol 750mg as 1 or 2 tablets 3 times per day.</p>	<p><u>Group 3:</u></p> <p>Naproxen 500mg twice per day.</p> <p>Placebo randomised to match the dosing patterns of group 1 and group 2.</p>	<p><u>1 week:</u></p> <p>RMDQ: Mean improvement: G1: 9.4 (95%CI 7.4 to 11.5), G2: 8.1 (95% CI 6.1 to 10.1), G3: 10.9 (95% CI 8.9 to 12.9). *</p> <p>Mean diff: G1 vs G3 1.5 (95%CI -1.4 to 4.3), G2 vs G3 2.8 (95%CI 0 to 5.7).</p> <p>Median days until usual activities: Differences: G1 vs G3: 0.2 (95%CI -0.7 to 1.0), G2 vs G3: 0.3 (95%CI -0.6 to 1.1), G1 vs G2: 0.1 (95%CI -0.8 to 1.0). *</p> <p>Worst LBP 24Hrs (%): Differences: G1 vs G3: 1 (95% CI -14 to 16), G2 vs G3: 5 (95% CI -11 to 20), G1 vs G2: 5 (95% CI -10 to 20). *</p> <p>Frequency of LBP 24hrs (%): Differences: G1 vs G3: 4 (95%CI -12 to 20), G2 vs G3: 7 (95%CI -8 to 23), G1 vs G2: 11 (95%CI -4 to 27). *</p> <p>Use of medication 24hrs (%): Differences: G1 vs G3: 4 (95%CI -12 to 20), G2 vs G3: 7 (95%CI -8 to 23), G1 vs G2: 11 (95%CI -4 to 27). *</p> <p>More than 80% of participants did not visit health care providers.</p> <p>Adverse events: G1: 7%, G2: 14%, G3: 13%.</p> <p><u>3 months:</u></p> <p>RMDQ (median): G1: 0 (IQR 0 to 4), G2: 0 (IQR 0 to 13), G3: 0 (IQR 0 to 8).*.</p> <p>Worst LBP 72hrs (% mild/none): G1: 55, G2: 58, G3: 55. *</p>
<p>Friedman, B. W. et al (2019, USA)</p> <p>Double blind RCT (35)</p>	<p>N=320</p> <p>Mean age: (39)</p> <p>Non-traumatic, non-radicular, musculoskeletal LBP</p> <p>RMDQ &gt;5</p> <p>Pain duration &lt;2 weeks</p>	<p><u>Group 2 (n=80):</u></p> <p>600mg ibuprofen plus 10-20mg baclofen orally 8 hourly.</p> <p><u>Group 3 (n=80):</u></p> <p>600mg ibuprofen plus 400-800mg metaxalone orally 8 hourly.</p> <p><u>Group 4 (n=80):</u></p> <p>600mg ibuprofen plus tizanidine 2-4 mg orally 8 hourly.</p>	<p><u>Group 1 (n=80):</u></p> <p>600mg ibuprofen plus placebo orally 8 hourly.</p>	<p><u>48 hours:</u></p> <p>% severe LBP: G1 62%, G2 48%, G3 55%, G4 47%.</p> <p>% frequent LBP: G1 38%, G2 30%, G3 36%, G4 31%.</p> <p>Medication use: G1 94%, G2 91%, G3 91%, G4 90%.</p> <p>Resumed usual activities: G1 47%, G2 51%, G3 41%, G4 46%</p> <p><u>1 week:</u></p> <p>Mean improvement RMDQ: G1 11.1 (95%CI 9.0-13.3), G2 10.6 (95%CI 8.6-12.7), G3 10.1 (95%CI 8.0-12.3), G4 11.2 (95%CI 9.2-13.2).</p> <p>% severe LBP: G1 30, G2 33, G3 37, G4 33.</p> <p>% frequent LBP: G1 16, G2 27, G3 32, G4 24.</p> <p>Medication use: G1 63, G2 62, G3 64, G4 63.</p> <p>Median days until usual activities: G1 2(IQR 2-7), G2 4(IQR 2-&gt;7), G3 3(IQR 2-7), G4 3(IQR 2-7).</p> <p>% Adverse events: G1 7, G2 10, G3 9, G4 8.</p>

<p>Friedman, B.W. et al (2020, USA) Double blind RCT (34)</p>	<p>N=120 Mean age: 41 Non-traumatic, non-radicular, musculoskeletal LBP RMDQ &gt;5 Pain duration &lt;2 weeks</p>	<p><u>Group 1: (n=60)</u> 600mg ibuprofen plus 500-1000mg acetaminophen orally 6 hourly.</p>	<p><u>Group 2: (n=60)</u> 600mg ibuprofen plus placebo orally 6 hourly.</p>	<p><u>48 hours:</u> RMDQ improvement: btwn G difference 0.1 (95%CI -3.4 to 3.5) % mild LBP: btwn G difference 3 (95%CI -15 to 21) % rare vs frequent LBP: btwn G difference 2 (95%CI -15 to 19) % no use of medication: btwn G difference 7 (95%CI 7 to 21)</p> <p><u>1 week:</u> Median RMDQ: G1 10 (IQR 0 to 20), G2 12 (IQR 0 to 18) %mild LBP: Btwn G difference 0 (95%CI -17 to 17). % rare vs frequent LBP: btwn G difference 1 (95%CI -18 to 19) % no use of medication: btwn G difference 2 (95%CI -11 to 20) Median days until usual activities: btwn G difference 0.6 (IQR -0.5 to 1.7) No visit to health care provider %: btwn G difference 7 (95%CI -4 to 17)</p>
<p>Guillen-Astete, C. A. et al (2017, Spain)  Retrospective observational study. (43)</p>	<p>N=732 Back pain Group 1: significantly younger, less men, more comorbidities, significantly higher VAS and significantly lower SF-36.</p>	<p><u>Group 1 (n=91):</u> Tapentadol. 23 received 25mg twice daily and 68 received 50mg twice daily.  15.4%(14) also received NSAID</p>	<p><u>Group 2 (n=641):</u> No tapentadol. 414 received tramadol: 44 TDD ≤37.5mg/d. 141 TDD &gt;37.5, ≤100mg. 172 TDD &gt;100mg, ≤200mg. 57 TDD &gt;200mg. 67.2%.  431 also received NSAID</p>	<p><u>7 days:</u> Pain VAS: G1: superior clinical evolution of pain (VAS and SF-36) than G2. P&lt;0.0001. In G2 patients who received tramadol had a better clinical evolution of pain vs no tramadol or tapentadol: p=0.007. <u>1 month:</u> Reassessment: G1: 20.9% vs G2: 50.3%. P&lt;0.0001 (OR 0.258, 95%CI 0.147 to 0.453). Significant reduction in reassessment in G1. Adverse effects G1: 3(3%) patients attended for adverse effects. G2: 3 (5%) patients attended for adverse effects. *</p>
<p>Innes et al (1998, Canada)  Double-blind RCT (39)</p>	<p>N=122 Moderate LBP (5-point verbal rating scale) Female: n=26 Age: 18 to 60 Weighing &gt;50kg Discharged within 2 to 4 hours Requiring oral analgesics</p>	<p><u>Group 1:</u> Oral 10mg ketorolac tromethamine, then the same every 4 to 6 hours as needed, up to 4 daily doses.  Rescue analgesia: oral 650mg acetaminophen.</p>	<p><u>Group 2:</u> Oral 600mg acetaminophen/ 60mg codeine, then the same every 4 to 6 hours as needed, up to 6 daily doses.</p>	<p><u>6 Hours:</u> Pain VAS: Peak pain intensity difference in both groups was 2.2hrs. G1 -25.5 (SD 17.9) G2 -27.7 (SD 17.9) no difference between groups. <u>1 week:</u> Pain VRS: Day 4: “a lot” or “complete” achieved by G1 53% (95%CI 40 to 66) and G2 55% (95%CI 42 to 68). No significant difference between groups at one week. Functional capacity: Both groups improved, no difference between groups (74% (62-86) vs 73% (61-74) reported “moderately” or “severely impaired” on day 1; 67% (55-79) vs 62% (50-74) on day 4 reported “No” or “mild impairment”). <u>1 month:</u></p>

				Overall drug rating: No significant difference between groups G1: 48% vs G2: 45% "very good" or "excellent. G1: 29% vs G2: 18% good, 23% vs 37% "fair" or "poor". Adverse effect: G2 2: 34% (95%CI 22-46) vs G1 64% (95%CI 52-76) p=0.0005.
Kocak, A. O. et al (2019, Turkey) Non-blinded Randomised study (30)	N=54 Mean age: 43 <48 hour onset non radicular LBP Presence of at least 1 trigger point	<u>Group 1:</u> Small amounts of local anesthetic (2% lidocaine, 2.5 cc from 100 mg-5 cc of ampoule with 2.5 cc saline) injected into trigger points	<u>Group 2:</u> 50 mg dexketoprofen in 100cc isoltolis solution over 5 minutes.	<u>Mean pain VAS:</u> 5 minutes: G1 2.77 (SD 2.81), G2 6.22 (SD 2.11) p<0.0001 10 minutes: G1 1.45 (SD 2.15), G2 5.22 (SD 2.41) p<0.0001 15 minutes: G1 0.82 (SD 1.71), G2 4.25 (SD 2.41) p<0.0001 30minutes: G1 0.55 (SD 1.6), G2 3.28 (SD 2.44) p<0.0001 60 minutes: G1 0.41 (SD 1.3), G2 2.59 (SD 2.37) p<0.0001 Respond to treatment (yes/no) G1 21/1, G2 20/12 p=0.008  <u>No adverse events.</u>
Miller et. al. (2015, USA)  Retrospective cohort comparison (36)	N=63 Severe LBP (axial +/- radiculopathy) Spondylosis Refractory to NSAIDs, muscle relaxants and IV narcotics treatment Female: n=31 Average age of 48 years	<u>Group 1:</u> After maximal attempts for pain relief in the ED failed, one Image- guided inter laminar epidural steroid injection.  Hospital admission for pain relief.	<u>Group 2:</u> After maximal attempts for pain relief in the ED failed.  Hospital admission for pain relief.	<u>2 weeks:</u> Cost of care: G1 \$4,800 (SD 2000) vs G2 \$33,000 (SD 14000) p<0.001. Significantly lower in G1. EDLOS: G1 8hrs (SD 3.6) vs G2 13hrs (SD4.2) p<0.002. Significantly less in G1.  Medication use: G1: 1/4 of hydromorphone dose and 1/3 of morphine dose while in ED, p<0.0001; 1/10 of hydromorphone dose and 1/18 of oxycodone dose prescribed, p<0.0001.  Consultant utilisation: G1 3 vs G2 18 times, p<0.0001. Admission time: G1 mean 0 days vs G2 mean 5 days, p<0.002.
Serinken, M. et al (2016, Turkey)  Double-blind RCT (21)	N=300 Age: 21 to 65 (mean=42.9) Sciatica and positive SLR 49.3% male Pain: <1 week, VAS>40mm.	<u>Group 1:</u> IV morphine (0.1mg/kg) in 100mls saline.  <u>Group 2:</u> IV paracetamol (1g) in 100mls saline.	<u>Group 3:</u> 100mls normal saline.  Fentanyl 1ug/kg rescue drug at 30mins if needed.	<u>30mins:</u> Pain VAS: Median changes: G1 54mm (95% CI=50-60mm), G2 29mm (95% CI=28-34mm), G3 12.5mm (95% CI 10-15).  Median changes between groups: G1 vs G2 25mm (95% CI=20-29mm), G1 vs G3 41mm (95% CI=37-45mm), G2 vs G3 16mm (95% CI=12-22mm).  Rescue fentanyl: G1 6% (95%CI=2-13.2), G2 18% (95% CI 10.7-28.5), G3 80% (95% CI 63-99).  Adverse effects: G1: 4 G2: 3 G3: 0

		Fentanyl 1ug/kg rescue drug at 30mins if needed.		
Serinken, M. Eken, C. et al (2016, Turkey)  Double-blind RCT (27)	N=140 Age: 18 to 65 (35+/- 12) 56% male Mechanical LBP (no sciatica) Pain <24hrs. VAS >40mm.	<u>Group 1:</u> 50mg IV dexketoprofen.  2g of 2.5% ketoprofen gel over approx 5cm diameter.	<u>Group 2:</u> 50mg IV dexketoprofen.  2g of placebo gel over approx 5cm diameter.	<u>15 mins:</u> Pain VAS: G1: mean reduction 27 (SD 13), G2: mean reduction 28 (SD13) Mean diff: 0.5 (95%CI -4 to 5) p=0.8 <u>30mins:</u> Pain VAS: G1: mean reduction, G2: mean reduction. Mean diff: 16 (95%CI 10-21) p=0.000. Significant improvement in G1. Rescue drug: G1 3%, G2 14%. Adverse events: 1 patient per group.
Tanen et al (2014, USA)  Double-blind RCT (28)	N=44 Acute radicular LBP Female: n=19 Age: 15 to 55 Pain >25mm VAS	<u>Group 1:</u> IV 100mg lidocaine over 2 minutes, followed by 10cc normal saline flush	<u>Group 2:</u> IV 30mg ketorolac over 2 minutes, followed by 10cc normal saline flush	<u>60 mins:</u> Pain VAS: G1: median reduction 8 (95%CI 0 to 23) p=0.003. G2: median reduction 14 (95%CI 0 to 28) p=0.007. P=0.835. * Clinical significance accepted by study: 13mm reduction in VAS. Rescue medication: G1 vs G2: 67% vs 50% p=0.35. * <u>1 week:</u> Pain Relief Scale 0-5: G1 vs G2: median differences 0 vs 0, p=0.388. *
Veenema et al (2000, USA)  Double-blind RCT (16)	N=155 LBP Female: n=60 Warrants parenteral Age: over 18 Pain VAS >70mm	<u>Group 1:</u> IM 1mg/kg meperidine	<u>Group 2:</u> IM 60mg ketorolac	<u>60 mins:</u> Pain VAS: Ketorolac 7mm (36 vs 29) less Pain Intensity Decrease than meperidine; 95% CI -15 to 2.6). Significant pain reduction in both groups. * Rescue analgesia: 37% vs 35%, (OR 0.47-1.74 95% CI) * Sedation: Sedation level by 3-point ordinal scale, adverse effects, rescue analgesia, 5-point patient satisfaction scale. Satisfaction: 74% vs 68%. * Adverse effects: G1 (41/75) vs G2 (8/80) 95%CI .27 to .63. More sedation in G1 (71% vs 24% "sedated" or "asleep, OR 3.54-17.4

217 Key: SD= Standard Deviation, CI= Confidence Interval, Mg= Milligrams, VRS= Visual Rating Scale, NRS= Numerical Rating Scale, G= Group, OR= Odds Ratio, ED= Emergency Department, IV= Intravenous,

218 IM=Intramuscular, LBP= Low back Pain, \*No significant difference between groups, ICD= International Classification of Disease Revision Codes, EDLOS= Emergency department length of stay, ODI= Oswestry disability

219 index, NSAID= Non-steroidal anti-inflammatory, TDD= total daily dose, SLR ROM=straight leg raise range of movement, VAS=visual analogue scale, RMDQ= Roland Morris Disability Index

220 **Table 2: Non-pharmacological interventions PICOS**

Authors, publication year, Country	Participants	Interventions	Comparisons	Outcomes
Cohen, M.M. et al (2017, Australia)  Pragmatic, multicentre, single blinded, RCT (32)	N= 528 (270 51% with LBP) Age: mean 41 years 47% female Pain VNRS >4	<u>Group 1:</u> Acupuncture alone: predetermined treatment protocol, plus additional points.  <u>Group 2:</u> Combined treatment: acupuncture and pharmacotherapy, 15 minutes apart to maintain blinding.	<u>Group 3:</u> Pharmacotherapy alone: standardised protocol based.  Back pain: diazepam, Hartmann's solution, paracetamol, paracetamol/codeine, tramadol, dextropropoxyphene and paracetamol, NSAID, IV morphine.	<u>1 hour</u> Pain NRS: Mean decrease: G1 1.9 (SD 2.3) G2 2.2 (SD2.2) G3 2.0 (SD2.3)* p=0.29. Rescue analgesia: G1 45 (25%) G2 27 (15%) G3 26 (15%) Significantly more use in G1 p=0.016. Satisfaction: * p=0.91 EDLOS: G1 3.8(IQR 2.9 to 4.9) G2 3.7(IQR 2.8 to 4.8), G3 3.9(IQR2.7 to 5.3).* p=0.87  <u>48 hours</u> Admission rate: G1 27(19%) G2 13(9.2%) G3 20(15%). Significantly more admissions in G1 p=0.07 ODI mean difference: G1 27.9 (12.7), G2 27.4 (11.5), G3 29.3 (11.1)* p=0.52.  No statistically significant change in any other outcome measure after 1 or 48 hours.
Fox, L. M. et al (2018, USA)  RCT: pilot study to examine feasibility and efficacy. (14)	N=30 Age: >18 years (mean 41) 56% female Acute or acute on chronic LBP	<u>Group 1:</u> Standard care (discretion of treating physician)  Battlefield acupuncture.  Protocol: indwelling semi-permanent needles	<u>Group 2:</u> Standard care (discretion of treating physician)	<u>Post intervention</u> Time to get up and go test: G1 21.3 (95% CI 18.2-24.5) G2 19 (95% CI 15.6-22.5) *p=0.33. LBP NRS: G1 5.2 (95% CI 4.2-6.2, G2 6.9 (95% CI 5.7-8.3). G1 significantly lower p=0.04. Leg pain NRS: G1 1.4 (95%CI 0.1 to 2.7) G2 2.2 (95%CI 0.7 to 3.5)* p=0.43  *flexion, extension  EDLOS, medication and adverse events were not reported.
Lau et al (2008, Hong Kong) Single blind RCT	N=110 Acute low back pain +/- leg referral Female: n=67	<u>Group 1:</u> Stay active advice, return early to normal activities, educational session,	<u>Group 2:</u> Conventional intervention: walking training, walking aids as indicated.	<u>Discharge from ED:</u> Pain NRS: Between group diff: -1.6(97.5%CI -2.3 to 0.8) Significantly less pain in group 1. RMDQ: Between group diff -0.3 (-2.8 to 2.2) BPS: Between group diff: -0.6(97.5%CI-1.7 to 0.6)

(22)	Age: 19-88 (mean 50) No previous episode of acute low back pain in the previous 6 months	mobility training, walking, 1 or 2 interferential therapy session.  Standard medical pain management.  Standard outpatient physiotherapy after discharge.	Standard medical pain management.  Standard outpatient physiotherapy after discharge.	Patient satisfaction: Between group diff 2.1 (97.5%CI 1.2 to 2.9) SF-12P: between group diff -2 (-6 to 2) SF-12M: between group diff 5 (0.3 to 9) <u>1 month:</u> Pain NRS: Between group diff -0.4 (-0.3 to 0.5) RMDQ: Between group diff -0.6 (-1.7 to 0.6) Satisfaction:* SF-12P: Between group diff -1 (-0.5 to 2) SF-12M : Between group diff 1 (-4 to 5) <u>6 months</u> *all outcome measures
Liu et al (2015, Taiwan)  Pilot cohort study (31)	N=59 Acute LBP Female: n=30 ICD-9 724.2 Lumbago Age: 20 to 90	<u>Group 1:</u> Fixed point acupuncture set protocol.  Needles stimulated until "De Qi" and stayed in place for 15 minutes.	<u>Group 2:</u> Fixed point sham acupuncture by pasting seed patches next to the set protocol points.	<u>After intervention:</u> Pain VAS. Median reduction: G1: 3 p<0.001, G2: 1 p=0.109. Significant difference between groups: p<0.001  Heart rate variability. * Adverse effects. None reported.  <u>3 days:</u> Pain VAS. Median reduction: G1: 4 p<0.001, G2: 2.5 p=0.011.* p=0.181
Sayer, J.M. et al (2018, Australia)  Retrospective audit	N=1565 Age: 18-65 years (42) 50% female LBP: ICD-10 M543, M545, M5499, S337, S390	<u>Group 1:</u> Seen by AMPs who had undertaken a competency based training and assessment program.	<u>Group 2:</u> Seen by non-AMP clinician (ED doctors and nurse practitioners)	<u>1 week</u> EDLOS: G1 141 mins G2 175min. Significantly less in G1 (p<0.001). Admissions rate: G1 36 G2 258. Significantly less in G1 (p<0.001).  <u>Audit period</u> Re-present: * 24hrs, 48hrs, 1 week, 1 year (p=0.26)

221 Key: G= Group, ED= Emergency Department, IV= Intravenous, IM=Intramuscular, LBP= Low back Pain, \*No significant difference between groups, ICD= International Classification of Disease Revision Codes, EDLOS=

222 Emergency department length of stay, ODI= Oswestry disability index, NSAID= Non-steroidal anti-inflammatory, TDD= total daily dose, SLR ROM=straight leg raise range of movement, VAS=visual analogue scale,

223 NRS=numerical rating scale, RMDQ= Roland Morris Disability Index, AMP= Advanced Musculoskeletal Physiotherapists, BPS= Back Performance Scale, RCT= Randomised Control Trial.

224

225



226

227

228

229

230

231

232 **Table 3: Downs and Black scores of pharmacological studies.**

Author(s) (Publication year)	Reporting (11)	External Validity (3)	Internal validity (7)	Selection bias (6)	Power (5)	Total score	Quality
Balakrishnamoorthy et al (2015) (17)	10	3	7	6	5	31	Excellent
Friedman et al (2006) (25)	10	3	7	6	5	31	Excellent
Friedman et al (2019) (35)	10	3	7	6	5	31	Excellent
Friedman et al (2015) (44)	11	3	6	5	5	30	Excellent
Friedman, Irizarry et al (2017) (24)	10	3	6	6	5	30	Excellent
Friedman et al (2020) (34)	10	2	7	6	5	30	Excellent
Serinken, Eken et al (2016) (27)	9	3	7	6	5	30	Excellent
Friedman, Ciewski et al (2018) (26)	10	3	5	5	5	28	Excellent
Akbas et al (2019) (29)	10	3	4	6	5	28	Excellent
Eken et al (2014) (19)	10	3	5	6	3	27	Excellent
Serinken et al (2016) (21)	9	2	6	5	5	27	Excellent
Guillen-Asete et al (2017) (43)	10	3	4	4	5	26	Good
Eskin et al (2014) (37)	10	2	5	5	3	25	Good
Behrbalk et al (2014) (18)	9	1	6	3	5	24	Good
Ergün et al (2010) (15)	9	3	6	2	3	23	Good
Innes et al (1998) (39)	11	1	6	5	0	23	Good
Friedman et al (2008) (20)	10	3	6	3	0	22	Good
Kocak et al (2019) (30)	10	2	5	4	0	21	Good
Tannen et al (2014) (28)	9	1	7	4	0	21	Good
Veenema et al (2000) (16)	9	1	7	4	0	21	Good
Miller et. al. (2015) (36)	9	1	4	2	0	16	Fair

233

234

235

236 **Table 4: Downs and Black scores of non-pharmacological studies.**

Author(s) (Publication year)	Reporting (11)	External Validity (3)	Internal validity( 7)	Selection bias (6)	Power (5)	Total score	Quality
Cohen et al (2017) (32)	9	3	6	5	5	28	Excellent
Sayer et al (2018) ( )	10	3	5	4	0	22	Good
Lau et al (2008) (33)	8	3	4	5	0	20	Fair
Liu et al (2015) (31)	10	1	6	3	0	20	Fair
Fox et al (2018) (14)	9	1	5	3	0	18	High

237

238 **Table 5: Grouped positive and negative finding of pharmacological studies**

Intervention	Positive Findings (context)[quality score of study]	Negative findings (context)[quality score of study]
Corticosteroids	IV dexamethasone: Reduced pain after 24 hours (-1.86 VAS compared to SC, radicular patients)[excellent] Reduced EDLOS (-15.3 hours compared to SC, radicular patients)[excellent](17)	IM methylprednisolone: Not superior to SC (patients with no neurological deficit) [excellent](25)
	IM methylprednisolone: Lower disability (-29% compared to SC, radicular patients)[good] Less analgesic use (-20% from SC, radicular patients)[good](20)	Oral prednisolone: More healthcare utilization (+22% compared to SC, patients with no neurological deficit)[good] More days lost from work (+0.9 days compared to SC, patients with no neurological deficit)[good](37)
	Epidural steroid: Lower healthcare cost, less medication and consultation utilized (Cost at \$4,800, compared to \$33,000 of SC, spondylosis patients after maximal pain reduction attempts failed)[fair](36)	
NSAIDs	Naproxen: As effective alone than combined with acetaminophen-codeine, or cyclobenzaprine (both short and long-term, no neurological deficit) [excellent](23) As effective alone than combined with Diazepam (non-radicular LBP)[excellent] As effective alone than combined with orphenadrine or methacarbamol (non-radicular LBP)[excellent](26)	IV dexketoprofen: Not superior to IV paracetamol or IV morphine (patients with no neurological deficit)[excellent](19)
	ketoprofen gel: 2g of 2.5% plus 50mg IV dexketoprofen superior to placebo plus 50mg IV	

	dexketoprofen (non-radicular LBP)[excellent](27)	
	IV Ketorolac: As effective as IV lidocaine, less need for rescue analgesia (radicular patients)[good](28)	
	IM Ketorolac: As effective as IM meperidine, better adverse effect profile (71% vs 24% of patients sedated or asleep) [good](16)	
	Oral Ibuprofen: As effective alone than combined with oral Baclofen, Metaxolone or Tizanidine (non-radicular LBP) [excellent] (35) As effective alone than combined with oral paracetamol (non-radicular LBP)[excellent] (34)	
Muscle relaxants		Cyclobenzaprine: Not superior to Naproxen alone (no neurological deficit)[excellent](23)
		Diazepam: Not superior to Naproxen alone (non-radicular LBP)[excellent](24)
		Methocarbamol: Not superior to naproxen alone (non-radicular LBP)[excellent](26)
		Phenyramidol: Not superior to placebo [good] (15)
		Baclofen, Metaxolone and Tizanidine: Not superior to placebo when combined with ibuprofen (non-radicular LBP)[excellent] (35)
Paracetamol	IV paracetamol: as effective as IV dexketoprofen and IV morphine (patients with no neurological deficit)[excellent](19)	IV paracetamol: Inferior to IV morphine, same adverse effect profile (radicular LBP)[excellent](21)
Opioids	IV morphine: Superior to IV paracetamol, same adverse effect profile (radicular LBP)[excellent](21)	Acetaminophen-codeine: Combined with Naproxen is not superior to Naproxen alone (short and long term, no neurological deficit)[excellent](23) Not superior to oral ketorolac (combined with acetaminophen), worse adverse effect profile (64% vs 34% of patients experienced adverse effects)[good]
	Tapentadol: Superior to other medications used in the ED, less need for reassessments (back pain)[good] (43)	IV morphine: Not superior to IV paracetamol or IV dexketoprofen (patients with no neurological deficit)[excellent](19)
Antihistamine (anxiolytic-sedative)		Promethazine: When combined with morphine, not superior to morphine alone in pain control, worse adverse effect profile (50% to 85% more sedation and

		drowsiness,) higher EDLOS (+78 minutes) [good](18)
Trigger point injections	Mesotherapy (thiocolchicoside, lidocaine, tenoxicam) of minimum 50 injections: Superior to IV dexketoprofen (radicular LBP)[excellent] (29)	
	Lidocaine: Superior to IV dexketoprofen (non-radicular LBP) [Good] (30)	

239 Key: IV Intravenous, SC Standard care, LBP low back pain, EDLOS Emergency department length of stay, IM intramuscular, VAS Visual

240 Analogue Scale, ED Emergency Department, Mg Milligrams

241 **Table 6: Grouped positive and negative finding of non-pharmacological studies**

Intervention	Positive findings (context) [Quality score of study]	Negative findings (context) [Quality score of study]
Physiotherapy	Physiotherapy assessment: Superior to Doctor or nurse assessment, significantly less EDLOS and admissions (back pain +/- sciatica)[good]	Physiotherapy intervention: Not superior at 6 month follow up. (back pain +/- radiculopathy)[fair]
	Physiotherapy intervention: Superior to SC for pain relief and function on discharge and 1 month follow up (back pain +/- radiculopathy)[fair]	
Acupuncture	More pain reduction than sham acupuncture post-treatment (2cm vs 0cm for sham acupuncture) no adverse effects [fair]	Not superior to acupuncture combined with SC pharmacotherapy and pharmacotherapy alone and has worse admission rates and need for rescue analgesia (LBP)[excellent]
	Significant reduction in pain post-treatment (mean 2.18, battlefield acupuncture, back pain) [fair]	No difference in pain at 3 days [fair]
		No significant difference in functional outcomes (battlefield, back pain) [fair]

242 Key: SC Standard care, EDLOS Emergency Department, LBP Low Back Pain,

243

244

- 245 1. Winter NDaNERSJ. Hospital Accident and Emergency Activity 2016-2017. In: care latfbha,  
246 editor. Government Statistical Service: NHS Digital; 2017.
- 247 2. Waterman BRMD, Belmont PJMD, Schoenfeld AJMD. Low back pain in the United States:  
248 incidence and risk factors for presentation in the emergency setting. Spine Journal, The.  
249 2012;12(1):63-70.
- 250 3. Machado GC, Rogan E, Maher CG. Managing non-serious low back pain in the emergency  
251 department: Time for a change? Emergency Medicine Australasia. 2018;30(2):279-82.

- 252 4. Friedman BW, Chilstrom M, Bijur PE, Gallagher EJ, Friedman BW, Chilstrom M, et al.  
253 Diagnostic testing and treatment of low back pain in United States emergency departments: a  
254 national perspective. *Spine (03622436)*. 2010;35(24):E1406-11.
- 255 5. Nunn ML, Hayden JA, Magee K. Current management practices for patients presenting with  
256 low back pain to a large emergency department in Canada. *BMC Musculoskeletal Disorders*.  
257 2017;18(1):92.
- 258 6. Ferreira GE, Machado GC, Shaheed CA, Lin CWC, Needs C, Edwards J, et al. Management of  
259 low back pain in Australian emergency departments. *BMJ QUALITY & SAFETY*. 2019;28(10):826-34.
- 260 7. Cantrill SV, Brown MD, Carlisle RJ. Clinical Policy: Critical issues in the prescribing of opioids  
261 for adult patients in the ED. *Spine* 2013;60(4). p. 17-22.
- 262 8. Kim HS, Strickland KJ, Mullen KA, Lebec MT. Physical therapy in the emergency department:  
263 A new opportunity for collaborative care. *The American Journal Of Emergency Medicine*. 2018;36(8)
- 264 9. Sutton M, Govier A, Prince S, Morphett M. Primary-contact physiotherapists manage a minor  
265 trauma caseload in the emergency department without misdiagnoses or adverse events: an  
266 observational study. *Journal of Physiotherapy*. 2015;61(2):77-80.
- 267 10. Liu J, Masiello I, Ponzer S, Farrokhnia N. Interprofessional teamwork versus fast track  
268 streaming in an emergency department-An observational cohort study of two strategies for  
269 enhancing the throughput of orthopedic patients presenting limb injuries or back pain. *PloS one*.  
270 2019;14(7):e0220011.
- 271 11. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the  
272 methodological quality of both randomised and non randomised studies of health care  
273 interventions. *Journal of Epidemiology and Community Health*. 1998;52(6) p. 377-84.
- 274 12. Deeks J, Dinnes J, D'Amico R, Snowden A, Sakarovitch C. Evaluating non-randomised  
275 intervention studies. *Health Technol Assess*. 2003;7(27)
- 276 13. Hooper PMDF, Jutai JWP, Strong GODM, Russell-Minda EMA. Age-related macular  
277 degeneration and low-vision rehabilitation: a systematic review. *Canadian Journal of*  
278 *Ophthalmology*. 2008;43(2):180-7.
- 279 14. Fox LM, Murakami M, Danesh H, Manini AF. Battlefield acupuncture to treat low back pain in  
280 the emergency department. *American Journal of Emergency Medicine*. 2018;36(6):1045-8.
- 281 15. Ergun H, Polat O, Demirkan A, Gunalp M, Gurler S. The efficacy, safety, and pharmacokinetics  
282 of intramuscular and oral phenylramidol in patients with low back pain in an emergency department.  
283 *Turkish Journal of Medical Science*. 2010;40(1):71-6.
- 284 16. Veenema KR, Leahey N, Schneider S. Ketorolac versus meperidine: ED treatment of severe  
285 musculoskeletal low back pain. *American Journal of Emergency Medicine*. 2000;18(4):404-7.
- 286 17. Balakrishnamoorthy R, Horgan I, Perez S, Steele MC, Keijzers GB. Does a single dose of  
287 intravenous dexamethasone reduce Symptoms in Emergency department patients with low Back  
288 pain and RAdiculopathy (SEBRA)? A double-blind randomised controlled trial. *Emergency Medicine*  
289 *Journal*. 2015;32(7):525-30.
- 290 18. Behrbalk E, Halpern P, Boszczyk BM, Parks RM, Chechik O, Rosen N, et al. Anxiolytic  
291 medication as an adjunct to morphine analgesia for acute low back pain management in the  
292 emergency department: a prospective randomized trial. *Spine*. 2014;39(1):17-22.
- 293 19. Eken C, Serinken M, Elicabuk H, Uyanik E, Erdal M. Intravenous paracetamol versus  
294 dexketoprofen versus morphine in acute mechanical low back pain in the emergency department: a  
295 randomised double-blind controlled trial. *Emergency Medicine Journal*. 2014;31(3):177-81.
- 296 20. Friedman BW, Esses D, Solorzano C, Choi HK, Cole M, Davitt M, et al. A randomized placebo-  
297 controlled trial of single-dose IM corticosteroid for radicular low back pain. *Spine (03622436)*.  
298 2008;33(18):E624-9.
- 299 21. Serinken M, Eken C, Gungor F, Emet M, Al B. Comparison of Intravenous Morphine Versus  
300 Paracetamol in Sciatica: A Randomized Placebo Controlled Trial. *Academic Emergency Medicine*.  
301 2016;23(6):674-8.

- 302 22. Lau PM, Chow DH, Pope MH. Early physiotherapy intervention in an Accident and Emergency  
303 Department reduces pain and improves satisfaction for patients with acute low back pain: a  
304 randomised trial. *Australian Journal of Physiotherapy*. 2008;54(4):243-9.
- 305 23. Friedman BW, Dym AA, Davitt M, Holden L, Solorzano C, Esses D, et al. Naproxen With  
306 Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A  
307 Randomized Clinical Trial. *JAMA*. 2015;314(15):1572-80.
- 308 24. Friedman BW, Irizarry E, Solorzano C, Khankel N, Zapata J, Zias E, et al. Diazepam Is No Better  
309 Than Placebo When Added to Naproxen for Acute Low Back Pain. *Annals Of Emergency Medicine*.  
310 2017;70(2):169-76.e1.
- 311 25. Friedman BW, Holden L, Esses D, Bijur PE, Choi HK, Solorzano C, et al. Parenteral  
312 corticosteroids for Emergency Department patients with non-radicular low back pain. *The Journal Of*  
313 *Emergency Medicine*. 2006;31(4):365-70.
- 314 26. Friedman BW, Cisewski D, Irizarry E, Davitt M, Solorzano C, Nassery A, et al. A Randomized,  
315 Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or  
316 Methocarbamol for Acute Low Back Pain. *Annals Of Emergency Medicine*. 2018;71(3):348-56.e5.
- 317 27. Serinken M, Eken C, Tunay K, Golcuk Y. Ketoprofen gel improves low back pain in addition to  
318 IV dexketoprofen: a randomized placebo-controlled trial. *American Journal of Emergency Medicine*.  
319 2016;34(8):1458-61.
- 320 28. Tanen DA, Shimada M, Danish DC, Dos Santos F, Makela M, Riffenburgh R. Intravenous  
321 lidocaine for the emergency department treatment of acute radicular low back pain, a randomized  
322 controlled trial. *The Journal of Emergency Medicine*. 2014;47(1):119-24.
- 323 29. Akbas I, Kocak AO, Kocak MB, Cakir Z. Comparison of intradermal mesotherapy with  
324 systemic therapy in the treatment of low back pain: A prospective randomized study. *The American*  
325 *journal of emergency medicine*. 2019; doi: 10.1016/j.ajem.2019.11.044. [Epub ahead of print]
- 326 30. Kocak AO, Ahiskalioglu A, Sengun E, Gur STA, Akbas I. Comparison of intravenous NSAIDs and  
327 trigger point injection for low back pain in ED: A prospective randomized study. *American Journal of*  
328 *Emergency Medicine*. 2019;37(10):1927-31.
- 329 31. Liu YT, Chiu CW, Chang CF, Lee TC, Chen CY, Chang SC, et al. Efficacy and Safety of  
330 Acupuncture for Acute Low back Pain in Emergency Department: A Pilot Cohort Study. *Evidence-*  
331 *Based Complementary and Alternative Medicine*. 2015;2015:1-9.
- 332 32. Cohen MM, Smit DV, Andrianopoulos N, Ben-Meir M, Taylor DM, Parker SJ, et al.  
333 Acupuncture for analgesia in the emergency department: a multicentre, randomised, equivalence  
334 and non-inferiority trial. *The Medical Journal Of Australia*. 2017;206(11):494-9.
- 335 33. Lau PMY, Chow DHK, Pope MH. Early physiotherapy intervention in an Accident and  
336 Emergency Department reduces pain and improves satisfaction for patients with acute low back  
337 pain: a randomised trial. *The Australian Journal Of Physiotherapy*. 2008;54(4):243-9.
- 338 34. Friedman BW, Irizarry E, Chertoff A, Feliciano C, Solorzano C, Zias E, et al. Ibuprofen Plus  
339 Acetaminophen Versus Ibuprofen Alone for Acute Low Back Pain: An Emergency Department–based  
340 Randomized Study. *Academic Emergency Medicine*. 2020;27(3)
- 341 35. Friedman BW, Irizarry E, Solorzano C, Zias E, Pearlman S, Wollowitz A, et al. A Randomized,  
342 Placebo-Controlled Trial of Ibuprofen Plus Metaxalone, Tizanidine, or Baclofen for Acute Low Back  
343 Pain. *Annals of Emergency Medicine*. 2019;74(4):512-20.
- 344 36. Miller T, Burns J, Gilligan J, Baffour F, Brook A. Patients with Refractory Back Pain Treated in  
345 the Emergency Department: Is Immediate Interlaminar Epidural Steroid Injection Superior to  
346 Hospital Admission and Standard Medical Pain Management? *Pain Physician*. 2015;18(2):E171-E6.
- 347 37. Eskin BMDP, Shih RDMD, Fiessler FWDO, Walsh BWMD, Allegra JRMDP, Silverman MEMD,  
348 et al. Prednisone for Emergency Department Low Back Pain: A Randomized Controlled Trial. *Journal*  
349 *of Emergency Medicine*. 2014;47(1):65-70.

- 350 38. Friedman BW, MDM, Irizarry EMD, Solorzano CP, Khankel NMD, Zapata JDO, Zias ER, et al.  
351 Diazepam Is No Better Than Placebo When Added to Naproxen for Acute Low Back Pain. *Annals of*  
352 *Emergency Medicine*. 2016;70(2):169-76.e1.
- 353 39. Innes G, Croskerry P, Worthington J, Beveridge R, Jones D. Ketorolac versus acetaminophen-  
354 codeine in the emergency department treatment of acute low back pain. *Journal of Emergency*  
355 *Medicine*. 1998;16(4):549-56.
- 356 40. Strudwick K, McPhee M, Bell A, Martin-Khan M, Russell T. Review article: Best practice  
357 management of low back pain in the emergency department (part 1 of the musculoskeletal injuries  
358 rapid review series). *Emergency Medicine Australasia*. 2018;30(1):18-35.
- 359 41. National Institute of Clinical Excellence. (2016) Low back pain and sciatica in over 16s:  
360 assessment and management (NG59). <https://www.nice.org.uk/guidance/ng59>
- 361 42. Bounes V, Charrion-Dadone B, Levraut J, Delangue C, Carpentier F, Mary-Chalon S, et al.  
362 Predicting morphine related side effects in the ED: An international cohort study. *American Journal*  
363 *of Emergency Medicine*. 2016;35(4):531-5.
- 364 43. Guillén-Astete CA, Cardona-Carballo C, de la Casa-Resino C. Tapentadol versus tramadol in  
365 the management of low back pain in the emergency department: Impact of use on the need for  
366 reassessments. *Medicine*. 2017;96(45):e8403-e.
- 367 44. Friedman BW, Dym AA, Davitt M, Holden L, Solorzano C, Esses D, et al. Naproxen With  
368 Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A  
369 Randomized Clinical Trial. *JAMA: Journal of the American Medical Association*. 2015;314(15):1572-  
370 80.

371

372